RDHL
Redhill Biopharma·NASDAQ
--
--(--)
--
--(--)
0.87 / 10
Underperform
Redhill Biopharma's fundamental quality is assessed as inadequate (0.9/10). Key concerns include a high Days sales outstanding of 174.06, indicating slow receivable collection, while revenue growth metrics (Total operating revenue YoY +58.59%) show mixed performance. The Interest coverage ratio of 27.58 provides some cushion, but overall the fundamentals remain weak, supporting a challenging investment stance.
Analysis Checks(1/4)
Total operating revenue (YoY growth rate %)
Value58.59
Score0/3
Weight42.13%
1M Return-6.11%
Value58.59
Score0/3
Weight42.13%
1M Return-6.11%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight9.09%
1M Return-1.11%
Value27.58
Score2/3
Weight9.09%
1M Return-1.11%
Days sales outstanding
Value174.06
Score1/3
Weight12.52%
1M Return-1.57%
Value174.06
Score1/3
Weight12.52%
1M Return-1.57%
Operating revenue (YoY growth rate %)
Value58.59
Score0/3
Weight36.26%
1M Return-5.06%
Value58.59
Score0/3
Weight36.26%
1M Return-5.06%
Total operating revenue (YoY growth rate %)
Value58.59
Score0/3
Weight42.13%
1M Return-6.11%
Value58.59
Score0/3
Weight42.13%
1M Return-6.11%
Days sales outstanding
Value174.06
Score1/3
Weight12.52%
1M Return-1.57%
Value174.06
Score1/3
Weight12.52%
1M Return-1.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight9.09%
1M Return-1.11%
Value27.58
Score2/3
Weight9.09%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value58.59
Score0/3
Weight36.26%
1M Return-5.06%
Value58.59
Score0/3
Weight36.26%
1M Return-5.06%
Is RDHL fundamentally strong?
- RDHL scores 0.87/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -97.52% net margin, -0.59 P/E ratio, -1.24 P/B ratio, and 100.00% earnings growth, these metrics solidify its Underperform investment rating.
